- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04461041
Empagliflozin and Cardiac Remodelling in People Without Diabetes (EMPA-HEART 2)
Study Overview
Status
Intervention / Treatment
Detailed Description
Sodium-glucose cotransporter 2 (SGLT2) inhibitors (empagliflozin, canagliflozin and dapagliflozin) are approved medications to improve glycemic control in adult patients with type 2 diabetes. When added to current standard-of-care diabetes treatment, SGLT2 inhibitors are associated with clinically meaningful reductions in major adverse cardiovascular events, reduced rates of hospitalization for heart failure and a decrease in major adverse kidney outcomes. Importantly, these benefits were observed consistently in people with and without type 2 diabetes and across all levels of baseline glycemic control. These data point towards a glucose-independent, cardioprotective effect of SGLT2 inhibition. How SGLT2 inhibition might reduce cardiac outcomes in people without diabetes remains unclear, and this is the specific objective of EMPA-HEART 2.
The study drug, empagliflozin (marketed as Jardiance), belongs to a class of medications that lowers blood glucose (sugar) by preventing glucose from entering back into blood circulation and ensures it is eliminated in urine. Empagliflozin is approved by the FDA and Health Canada for the treatment of type 2 diabetes.
This is a double-blind, randomized, placebo-controlled, parallel-group study of empagliflozin vs. placebo in patients without diabetes but with various cardiovascular risk factors. The purpose is to determine the effects of empagliflozin on cardiac structure by using cMRI. Patients who have given informed consent will undergo a baseline cMRI and will then be randomly assigned in a 1:1 basis to either empagliflozin 10 mg once daily or matching placebo. An end of study cMRI will be performed at 26 weeks (6 months after starting the study drug).
The study subjects will be followed for 6 months. The patients will be assessed using cMRI, which is considered the "gold standard" for measuring left ventricular (LV) volume, mass, and ejection fraction. The investigators will assess changes from baseline in LV mass, LV end-diastolic volume, end-systolic volume, LV ejection fraction, LV diastolic and systolic function, and LV wall stress via cMRI in enrolled patients treated with empagliflozin compared to those who receive placebo. Additionally, changes from baseline in blood pressure, hematocrit, and biomarkers involved in the pathophysiology of heart failure, namely NT-proBNP, will be evaluated at 6 months.
Study assessments and potential adverse events reporting will be undertaken at each study visit.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Subodh Verma, MD PhD
- Phone Number: 416 864 5997
- Email: Subodh.Verma@unityhealth.to
Study Contact Backup
- Name: Val Panzov, MD
- Phone Number: 47125 416 360 4000
- Email: Val.Panzov@unityhealth.to
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Female Not of childbearing potential and male subjects ≥ 18 and ≤ 85 years of age (Women Not of childbearing potential are females who are permanently sterile or postmenopausal. Postmenopausal is defined as 12 consecutive months with no menses without an alternative medical cause or ≥6 weeks post-surgical bilateral oophorectomy prior to Screening.)
≥1 of the major criteria or ≥2 of the minor criteria below:
Major criteria
- Increased LVMi of ≥96 g/m2 for women and ≥116 g/m2 for men (as calculated by echocardiogram); or LVMi ≥81 g/m2 for women and ≥85 g/m2 for men (as calculated by cMRI)
- ECG evidence of LV hypertrophy (as per the Sokolow-Lyon criteria)
- Structural heart disease defined as interventricular septal thickness or posterior wall thickness at end-diastole of ≥11 mm (as measured by 2D echocardiography or cMRI)
- Persistent hypertension (defined as office blood pressure ≥140/90 mmHg) despite being on ≥3 antihypertensive medications
Minor criteria
- Prior history of a myocardial infarction (≥3 months ago)
- eGFR ≥30 and ≤60 mL/min/1.73 m2 (as measured by the CKD-EPI formula)
- Body mass index (BMI) ≥27 kg/m2
- Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures
Exclusion Criteria:
- Female subjects who are pregnant, lactating or of childbearing potential, or are pre-menopausal
- Known type 1 or type 2 diabetes
- Hemoglobin A1C (A1C) ≥6.5%
- eGFR <30 mL/min/1.73m2
- Known history of severe liver disease (e.g. Child Pugh Class B or C)
- Known history of severe symptomatic untreated anemia in the last 3 months (e.g. hemoglobin < 90 g/L)
- History of ketoacidosis, or increased chance of developing diabetic ketoacidosis (DKA) e.g. patients who suffer from excessive vomiting, diarrhea, or sweating; subjects who are on a very low carbohydrate diet; or subjects who drink a lot of alcohol.
- Systolic blood pressure <95mmHg (as measured at the office/clinic visit)
- Subjects in whom coronary revascularization by either percutaneous coronary intervention or bypass surgery is being contemplated within the next 6 months, or who have undergone coronary revascularization in the prior 3 months
- Significant allergy or known intolerance to SGLT2is or any ingredient in the formulations
- Subjects currently experiencing any clinically significant or unstable medical condition that in the opinion of the investigator might limit their ability to complete the study, or to comply with the requirements of the protocol, including: dermatologic disease, hematological disease, pulmonary disease, hepatic disease, gastrointestinal disease, genitourinary disease, endocrine disease, neurological disease, and psychiatric disease
- Any malignancy not considered cured (except basal cell carcinoma of the skin). A subject is considered cured if there has been no evidence of cancer recurrence for the 5 years prior to screening
- Subjects who have participated in other interventional studies which may affect any of the primary or secondary outcomes of the study within 30 days of the screening visit
- Contraindications or inability to undergo magnetic resonance imaging such as severe obesity (e.g. weight >500 lbs) or the presence of metallic fragments, clips, or devices
- Known history of infiltrative cardiomyopathy such as cardiac amyloidosis or cardiac sarcoidosis
- Severe aortic stenosis
- Severe aortic regurgitation
- Severe mitral stenosis
- Severe mitral regurgitation
- Low voltage on ECG limb leads defined by the amplitude of the QRS complex in each limb lead ≤0.5 mV
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Empagliflozin
Single 10 mg tablet, administered orally once daily for 6 months
|
Single oral tablet
Other Names:
|
Placebo Comparator: Placebo
Single 10 mg tablet, administered orally once daily for 6 months
|
Placebo tablet manufactured to mimic empagliflozin 10 mg tablet
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Left Ventricular (LV) mass
Time Frame: 6 months
|
Change in Left Ventricular (LV) mass (indexed to body surface area (BSA)) at 6 months.
This will be measured using CMRI.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
LV end-diastolic volume
Time Frame: 6 months
|
Change in LV end-diastolic volume (indexed to BSA) at 6 months.
This will be measured using CMRI.
|
6 months
|
LV end-systolic volume
Time Frame: 6 months
|
Change in LV end-systolic volume (indexed to BSA) at 6 months.
This will be measured using CMRI.
|
6 months
|
Left Ventricular Ejection Fraction (LVEF)
Time Frame: 6 months
|
Change in LVEF at 6 months.
This will be measured using CMRI.
|
6 months
|
LV wall stress
Time Frame: 6 months
|
Change in LV wall stress at 6 months.
This will be measured using CMRI.
|
6 months
|
LV systolic function
Time Frame: 6 months
|
Change in LV systolic function at 6 months.
This will be measured using CMRI.
|
6 months
|
LV diastolic function
Time Frame: 6 months
|
Change in LV diastolic function at 6 months.
This will be measured using CMRI.
|
6 months
|
NT-proBNP
Time Frame: 6 months
|
Change in circulating NT-proBNP at 6 months.
|
6 months
|
Systolic and diastolic blood pressure
Time Frame: 6 months
|
Change in systolic and diastolic blood pressure at 6 months.
|
6 months
|
Hematocrit
Time Frame: 6 months
|
Change in hematocrit at 6 months in patients.
|
6 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Subodh Verma, MD PhD, Unity Health Toronto
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1245-0206
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Diseases
-
Oregon Health and Science UniversityCompletedCardiovascular Disease | Cardiovascular Risk FactorsUnited States
-
Medical College of WisconsinRecruitingCardiovascular Diseases | Cardiovascular Risk Factor | Cardiovascular HealthUnited States
-
Hospital Mutua de TerrassaCompleted
-
Women's College HospitalUniversity Health Network, Toronto; Sunnybrook Health Sciences Centre; Brigham... and other collaboratorsUnknownCARDIOVASCULAR DISEASESCanada, United States
-
Groupe Hospitalier Paris Saint JosephTerminatedCARDIOVASCULAR DISEASESFrance
-
University of FloridaUniversity of Alabama at Birmingham; Brown UniversityCompletedCardiovascular Disease | Psychosocial Influence on Cardiovascular DiseaseUnited States
-
Nanjing Medical UniversityRecruiting
-
Centre Hospitalier Universitaire de la RéunionRecruitingCardiovascular DiseaseFrance
-
National Heart, Lung, and Blood Institute (NHLBI)RecruitingCardiovascular DiseaseUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)RecruitingCardiovascular DiseaseUnited States
Clinical Trials on Empagliflozin
-
Boehringer IngelheimEli Lilly and CompanyCompletedDiabetes Mellitus, Type 1Austria, Germany
-
Boehringer IngelheimEli Lilly and CompanyCompletedDiabetes Mellitus, Type 1Japan
-
University Medical Centre LjubljanaUnknownDiabetes Complications | Diabetes Mellitus, Type 1 | Vascular Stiffness | Hypoglycemic AgentsSlovenia
-
Boehringer IngelheimEli Lilly and CompanyCompleted
-
Boehringer IngelheimEli Lilly and CompanyCompletedDiabetes Mellitus, Type 2United States, Australia, Canada, Estonia, France, Georgia, Germany, Guatemala, Italy, Latvia, Lithuania, Mexico, New Zealand, Poland, Russian Federation, South Africa, Spain, Ukraine
-
Boehringer IngelheimEli Lilly and CompanyCompletedDiabetes Mellitus, Type 2United States, France, Israel, Mexico, South Africa
-
Boehringer IngelheimCompleted
-
Collegium Medicum w BydgoszczyRecruitingMetabolic SyndromePoland
-
Boehringer IngelheimEli Lilly and CompanyCompleted
-
Boehringer IngelheimEli Lilly and CompanyCompletedHypertension | Diabetes Mellitus, Type 2United States